Europe Digital PCR Market Report 2024-2034, Competitive Analysis of QIAGEN, F. Hoffmann-La Roche, Merck, Stilla Technologies, SAGA Diagnostics, and JETA Molecular - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Europe Digital PCR Market: Focus on Application, End User, and Country Analysis - Analysis and Forecast, 2024-2034" report has been added to ResearchAndMarkets.com's offering.

The Europe digital PCR (d-PCR) market is projected to reach $762.7 million by 2034 from $183.9 million in 2024, growing at a CAGR of 15.29% during the forecast period 2024-2034

The market for digital PCR is growing quickly in Europe due to the growing use of personalised medicine and the need for extremely accurate diagnostics. With its remarkable sensitivity and specificity, digital PCR (dPCR) is especially useful for identifying low-abundance genetic mutations and measuring biomarkers that are essential for early diagnosis and treatment monitoring. Increasing rates of infectious diseases, genetic disorders, and cancers have prompted investments in cutting-edge molecular diagnostic technologies.

The accuracy, throughput, and ease of integration of assays into clinical workflows have been greatly enhanced by technological advancements like droplet digital PCR, nanoplate technology, and microfluidic platforms. Furthermore, market adoption has accelerated throughout the continent due to government initiatives, favourable regulatory frameworks, and increased funding for healthcare infrastructure.

The European digital PCR market is expected to grow steadily as top research institutes and business leaders keep working together to create reliable, patient-specific diagnostic solutions. In addition to changing the molecular diagnostics landscape, this dynamic market is opening the door for individualised treatment plans that improve patient outcomes.

Overall, the convergence of technological innovation, regulatory support, and evolving clinical demands is driving the digital PCR market's robust expansion in Europe. Additionally, growing research collaborations and investments will further integrate digital PCR in Europe.

How can this report add value to an organization?

Product/Innovation Strategy: The Europe digital PCR market has been extensively segmented based on various categories, such as application, end user, and country. This can help readers understand which segments account for the largest share and which are well-positioned to grow in the coming years.

Growth/Marketing Strategy: Mergers, acquisitions, and product launches accounted for the maximum number of key developments.

Competitive Strategy: The Europe digital PCR market has numerous established players with product portfolios. Key players in the Europe digital PCR market analyzed and profiled in the study involve established players offering products for digital PCR.

Key Market Players

• QIAGEN N.V.
• F. Hoffmann-La Roche Ltd
• Merck KGaA
• Stilla Technologies Inc.
• SAGA Diagnostics AB
• JETA Molecular BV.

Key Attributes:

Report Attribute	Details
No. of Pages	72
Forecast Period	2024 - 2034
Estimated Market Value (USD) in 2024	$183.9 Million
Forecasted Market Value (USD) by 2034	$762.7 Million
Compound Annual Growth Rate	15.2%
Regions Covered	Europe

Key Topics Covered:

Executive Summary

Scope and Definition

1 Markets

1.1 Market Overview

1.1.1 Workflow of Digital PCR

1.1.2 Comparison of qPCR and dPCR

1.2 Trends: Current and Future Impact Assessment

1.2.1 Integration with Next-Generation Sequencing (NGS)

1.2.2 Increased Real-time Monitoring and Point-of-care Applications of Digital PCR

1.2.3 Increasing Product Launches in d-PCR Ecosystem

1.3 Supply Chain Overview

1.4 Research and Development Review

1.4.1 Patent Filing Trend (by Region)

1.4.2 Patent Filing Trend (by Country)

1.4.3 Patent Filing Trend (by Year)

1.5 Ongoing Digital PCR Clinical Trials

1.6 Regulatory Landscape

1.6.1 European Union

1.7 Market Dynamics Overview

1.7.1 Market Drivers

1.7.1.1 Increasing Adoption of Personalized Medicine for Screening and Diagnostics of Genetic Disorders such as Rare Diseases and Cancer

1.7.1.2 Increasing Incidence of Infectious Diseases

1.7.1.3 Technological Advancement in dPCR to Enhance Market Growth

1.7.2 Market Restraints

1.7.2.1 High Cost of Platforms Associated with Digital-PCR

1.7.2.2 Shortage of Skilled Professionals and Trained Laboratory Technicians

1.7.3 Market Opportunities

1.7.3.1 Increased Use of Digital-PCR-Based Solutions for the Development of Therapeutics Drugs and Comprehensive Treatment Plan

1.7.3.2 Growing Adoption of dPCR in Emerging Markets

2 Regions

2.1 Regional Summary

2.2 Drivers and Restraints

2.3 Europe

2.3.1 Regional Overview

2.3.2 Driving Factors for Market Growth

2.3.3 Factors Challenging the Market

2.3.4 By Application

2.3.5 By End User

2.3.6 France

2.3.7 Germany

2.3.8 U.K.

2.3.9 Spain

2.3.10 Italy

2.3.11 Rest-of-Europe

3 Markets - Competitive Benchmarking & Company Profiles

3.1 Competitive Landscape

3.1.1 Mergers and Acquisitions

3.1.2 Synergistic Activities

3.1.3 Product Launch and Approval Activities

3.1.4 Expansion, Funding, and Other Activities

3.2 Market Share Analysis

3.3 Company Profile

3.3.1 Overview

3.3.2 Top Products/Product Portfolio

3.3.3 Top Competitors

3.3.4 Target Customers

3.3.5 Key Personnel

3.3.6 Analyst View

4 Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/7h8tyr

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.